

Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials

Kenneth B. Gordon,¹ Diamant Thaçi,² Melinda Gooderham,³ Yukari Okubo,⁴ Bruce Strober,⁵ Luke Peterson,⁶ Delphine Deherder,⁷ José M. López Pinto,⁸ Paolo Gisondi⁹

Objectives

To evaluate bimekizumab (BKZ) safety data up to 4 years in patients with moderate to severe plaque psoriasis, using the largest pool of phase 3/3b safety data at the time of this study.

To assess whether rates of treatment-emergent adverse events (TEAEs) changed with each year of BKZ treatment.

Introduction

- BKZ is a monoclonal immunoglobulin G1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.¹
- Psoriasis is a chronic condition requiring long-term management; thus evaluating long-term safety of treatments is essential to informing decision-making for clinicians, while managing risk for patients.²
- We report the first 4-year safety data for BKZ in patients with moderate to severe psoriasis.

Methods

- Data were pooled from the BE SURE, BE VIVID, and BE READY phase 3 trials, their open-label extension (OLE) BE BRIGHT, the BE RADIANT phase 3b trial, and the BE RADIANT OLE.³⁻⁷ The BE RADIANT trial ran for 3 years; therefore, the overall total pooled exposure only included BE RADIANT data to Year 3, in addition to BE BRIGHT data to Year 4. Data were pooled for all patients who received ≥1 BKZ dose in the included studies (Figure 1).
- Included patients received BKZ 320 mg every 4 weeks (Q4W) or every 8 weeks (Q8W); all received Q8W from Week 64 (BE RADIANT)/OLE Week 48 (BE BRIGHT) or the next scheduled clinic visit. Patients who switched from adalimumab, ustekinumab, or secukinumab to BKZ in BE SURE, BE VIVID, and BE RADIANT, respectively, were also included following the switch to BKZ.
- TEAEs were reported over 4 years using exposure-adjusted incidence rates (EAIRs) per 100 patient-years (PY).
- TEAEs were evaluated separately for Years 1, 2, 3, and 4 (Weeks 0–52, 52–104, 104–156, and 156–208) of BKZ treatment.

Results

- Total BKZ exposure was 6,324.3 PY (N=2,186; Year 1, Year 2, Year 3, Year 4: 2,053.3 PY [n=2,186], 1,904.3 PY [n=2,013], 1,521.1 PY [n=1,803], 819.5 PY [n=1,309]; Table 1).
- TEAEs occurred at an EAIR of 170.5/100 PY (Year 1, Year 2, Year 3, Year 4: 230.9/100 PY, 137.7/100 PY, 107.1/100 PY, 99.9/100 PY), serious TEAEs at 5.5/100 PY (6.5/100 PY, 5.9/100 PY, 5.8/100 PY, 5.6/100 PY), and TEAEs leading to discontinuation at 2.9/100 PY (4.6/100 PY, 2.3/100 PY, 2.3/100 PY, 1.1/100 PY). Overall, the EAIR of TEAEs decreased with longer BKZ exposure over 4 years (Figure 2).
- The most common TEAEs were nasopharyngitis at 12.7/100 PY (Year 1, Year 2, Year 3, Year 4: 25.8/100 PY, 13.2/100 PY, 5.4/100 PY, 5.9/100 PY), oral candidiasis at 8.9/100 PY (18.9/100 PY, 10.7/100 PY, 6.8/100 PY, 5.4/100 PY), and upper respiratory tract infection at 5.7/100 PY (10.4/100 PY, 5.7/100 PY, 3.7/100 PY, 3.9/100 PY; Table 2).
- Fewer TEAEs over 4 years occurred with BKZ Q8W versus (vs.) Q4W (115.4/100 PY vs. 224.4/100 PY), including for oral candidiasis (6.5/100 PY vs. 16.7/100 PY).

Conclusions

Bimekizumab demonstrated good tolerability and a comparable safety profile over 4 years in patients with moderate to severe plaque psoriasis.

EAIRs of TEAEs remained consistent or decreased with longer bimekizumab exposure over 4 years, with no new safety signals observed.

Summary




Figure 1 Included studies




Table 1 Summary of exposure and TEAEs

Weeks	BKZ Total				
	Year 1 N=2,186	Year 2 N=2,013	Year 3 N=1,803	Year 4 N=1,309	Overall N=2,186
Total exposure, PY	2,053.3	1,904.3	1,521.1	819.5	6,324.3 ^c
Mean exposure ± SD, days	345.7 ± 63.4	340.9 ± 62.2	328.5 ± 58.8	237.0 ± 94.0	988.4 ± 388.5
Median exposure (range), days	364 (23–364)	364 (1–364)	364 (7–364)	281 (1–364)	1,013 (23–1,569)
TEAE summary, EAIR/100 PY (95% CI)					
Any TEAE	230.9 (220.4, 241.8)	137.7 (130.5, 145.2)	107.1 (100.6, 114.0)	99.9 (91.5, 108.8)	170.5 ^d (163.2, 178.1)
Serious TEAEs	6.5 (5.5, 7.8)	5.9 (4.9, 7.1)	5.8 (4.6, 7.1)	5.6 (4.1, 7.5)	5.5 ^e (4.9, 6.2)
TEAEs leading to discontinuation	4.6 (3.7, 5.6)	2.3 (1.7, 3.1)	2.3 (1.6, 3.2)	1.1 (0.5, 2.1)	2.9 (2.5, 3.3)
Severe TEAEs	6.0 (5.0, 7.2)	5.0 (4.1, 6.2)	4.8 (3.7, 6.0)	5.1 (3.7, 6.9)	4.8 (4.3, 5.4)
TEAEs leading to death	0.3 (0.1, 0.6)	0.3 (0.1, 0.7)	0.5 (0.2, 0.9)	0.2 (0.0, 0.9)	0.3 (0.2, 0.5)

Data were pooled for all patients who received ≥1 BKZ dose in each of the periods examined (BKZ Total). ^aAll patients were switched to BKZ 320 mg Q8W at the next scheduled clinic visit on or after the Week 64/Week 104 visit (BE RADIANT/BE BRIGHT) following protocol amendment; ^bEntire pooled study period; ^cTotal BKZ exposure over 4 years is greater than the sum of BKZ exposure in individual years, as data beyond Week 208 were included due to the use of a cut-off date; ^dThe EAIR of TEAEs over 4 years was numerically lower in patients receiving BKZ Q8W vs. Q4W (115.4/100 PY vs. 224.4/100 PY); ^eThe rate of serious TEAEs over 4 years is lower than the rate in any individual year due to time not accounted for in the individual year summaries.

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BKZ: bimekizumab; CI: confidence interval; COVID-19: coronavirus disease 2019; EAIR: exposure-adjusted incidence rate; IL: interleukin; OLE: open-label extension; PY: patient-years; Q4W: every 4 weeks; Q8W: every 8 weeks; SD: standard deviation; TEAE: treatment-emergent adverse event; ULN: upper limit of normal; vs.: versus.

Institutions: ¹Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ²Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany; ³SKIN Centre for Dermatology, Proby Medical Research, Peterborough and Queen's University, Kingston, ON, Canada; ⁴Department of Dermatology, Tokyo Medical University, Tokyo, Japan; ⁵Department of Dermatology, Yale University, New Haven, CT, USA; ⁶Central Connecticut Dermatology Research, Cromwell, CT, USA; ⁷UCB, Morrisville, NC, USA; ⁸UCB, Braine-l'Alleud, Belgium; ⁹UCB, Madrid, Spain; ¹⁰Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

References: ¹Adams R et al. Front Immunol 2020;11:1894. ²Al-Janabi A & Yiu ZZN. Psoriasis (Auckl) 2022;12:1–14. ³Warren RB et al. N Engl J Med 2021;385(2):130–141. ⁴NCT03412747. ⁵Reich K et al. Lancet 2021;397(10273):487–498. ⁶NCT03370133. ⁷Gordon KB et al. JAMA Dermatol 2022;158(7):735–744. ⁸NCT03598790. ⁹Reich K et al. N Engl J Med 2021;385(2):142–152. ¹⁰NCT03536884. **Author Contributions:** Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: **KBG, DT, MG, YO, BS, LP, DD, JMPLP, PG.** Drafting of the publication, or reviewing it critically for important intellectual content: **KBG, DT, MG, YO, BS, LP, DD, JMPLP, PG.** Final approval of the publication: **KBG, DT, MG, YO, BS, LP, DD, JMPLP, PG.** **Author Disclosures:** **KBG:** Received consulting fees from AbbVie, Almiral, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dermira, Eli Lilly and Company, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; research support from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, and UCB. **DT:** Investigator and/or consultant/advisor for AbbVie, Almiral, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Galderma, Johnson and Johnson, Kyowa Kirin, LEO Pharma, L'Oréal, Newbridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Target-RWE, UCB, and Vichy; received grants from AbbVie, LEO Pharma, and Novartis. **MG:** Investigator, speaker, consultant or advisory board member for AbbVie, Acelyrin, Akros, Amgen, AnasysBio, Arcutis, Arista, ASLAN Pharmaceuticals, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Incyte, JAMP Pharma, Janssen, Kyowa Kirin, L'Oréal, MedImmune, Meiji, MoonLake Immunotherapeutics, Nektar Therapeutics, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Sanofi, Sun Pharma, Takeda, Tarsus, UCB, Union, and Ventyx. **YO:** Received research grants from Eisai, Maruho, Shiseido, and Torii Pharmaceutical; consulting and advisory board agreements from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Janssen, and Sun Pharma; speaker's bureau from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly and Company, Janssen, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho Pharmaceutical, Tanabe-Mitsubishi, Torii Pharmaceutical, and UCB; clinical trials sponsored by AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Maruho, Pfizer, Sun Pharma, and UCB. **BS:** Consultant (honoraria) for AbbVie, Alumis, Almiral, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Capital One, CorEvitas, Dermavant, Janssen, Leo, Eli Lilly, Maruho, Oruka, Meiji Seika Pharma, Protagonist, Takeda, Novartis, Pfizer, UCB, Rapit, Regeneron, Sanofi, Genzyme, Union Therapeutics; stock options from Connect Biopharma, Mindera Health; speaker for AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, Janssen, Regeneron, and Sanofi Genzyme; scientific co-director (consulting fee) for CorEvitas Psoriasis Registry; investigator for CorEvitas Psoriasis Registry; editor-in-chief (honorarium) of Journal of Psoriasis and Psoriatic Arthritis. **LP, DD, JMPLP:** Employees and shareholders of UCB. **PG:** Consultant for AbbVie, Abiogen, Almiral, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Merck, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Sanofi, and UCB. **Acknowledgments:** These studies were funded by UCB. We would like to thank the patients and their caregivers in addition to the investigators and their teams who contributed to these studies. The authors acknowledge Susanne Wiegartz, MSc, UCB, Monheim am Rhein, Germany, and Joe Dixon, PhD, UCB, Slough, UK, for publication coordination, Sana Year, PhD, Costello Medical, Manchester, UK, for medical writing support and editorial assistance, and Danielle Hart of the Creative team at Costello Medical, London, UK, for graphic design assistance. All costs associated with development of this poster were funded by UCB.

Figure 2 Incidence rates of TEAEs: Any, serious, and discontinuations over time (BKZ Total)




Table 2 Most common TEAEs and TEAEs of interest (BKZ Total)

	Year 1 N=2,186	Year 2 N=2,013	Year 3 N=1,803 ^a	Year 4 N=1,309 ^a	Overall N=2,186
Most common TEAEs, EAIR/100 PY (95% CI)					
Nasopharyngitis	25.8 (23.5, 28.3)	13.2 (11.6, 15.0)	5.4 (4.3, 6.7)	5.9 (4.4, 7.9)	12.7 (11.7, 13.8)
Oral candidiasis	18.9 (16.9, 21.0)	10.7 (9.2, 12.3)	6.8 (5.6, 8.3)	5.4 (3.9, 7.3)	8.9 (8.1, 9.7) ^b
Upper respiratory tract infection	10.4 (9.0, 12.0)	5.7 (4.7, 6.9)	3.7 (2.8, 4.9)	3.9 (2.6, 5.5)	5.7 (5.1, 6.4)
TEAEs of interest, EAIR/100 PY (95% CI)					
Serious infections	1.7 (1.2, 2.3)	0.8 (0.5, 1.4)	1.4 (0.9, 2.1)	1.1 (0.5, 2.1)	1.3 (1.0, 1.6)
Active tuberculosis	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
Fungal infections	30.6 (28.0, 33.3)	18.8 (16.8, 21.0)	11.9 (10.2, 13.8)	8.6 (6.6, 10.9)	15.7 (14.6, 16.9)
Candida infections	22.2 (20.1, 24.4)	12.8 (11.2, 14.6)	7.8 (6.5, 9.4)	5.7 (4.1, 7.6)	10.4 (9.5, 11.3)
Oral candidiasis	18.9 (16.9, 21.0)	10.7 (9.2, 12.3)	6.8 (5.6, 8.3)	5.4 (3.9, 7.3)	8.9 (8.1, 9.7) ^b
Adjudicated inflammatory bowel disease ^c	0.3 (0.1, 0.7)	0.2 (0.0, 0.5)	0.1 (0.0, 0.4)	0.1 (0.0, 0.7)	0.2 (0.1, 0.3)
Adjudicated major adverse cardiac event	0.5 (0.3, 1.0)	0.3 (0.1, 0.7)	0.6 (0.3, 1.1)	1.1 (0.5, 2.1)	0.6 (0.4, 0.8)
Malignancies	0.9 (0.6, 1.5)	1.1 (0.7, 1.7)	0.9 (0.5, 1.5)	1.0 (0.4, 1.9)	0.9 (0.6, 1.1)
Excluding non-melanoma skin cancer	0.4 (0.2, 0.8)	0.6 (0.3, 1.1)	0.7 (0.4, 1.3)	0.9 (0.3, 1.8)	0.6 (0.4, 0.8)
Adjudicated suicidal ideation and behavior	0.1 (0.0, 0.4)	0.2 (0.0, 0.5)	0.1 (0.0, 0.5)	0.0 (0.0, 0.0)	0.1 (0.1, 0.2)
Neutropenia events	0.8 (0.5, 1.3)	0.5 (0.3, 1.0)	0.1 (0.0, 0.5)	0.2 (0.0, 0.9)	0.5 (0.3, 0.7)
ALT or AST elevations					
>3x ULN	2.6 (1.9, 3.4)	2.4 (1.7, 3.2)	1.9 (1.3, 2.8)	1.8 (1.0, 3.0)	1.9 (1.6, 2.3)
>5x ULN ^d	0.8 (0.5, 1.3)	0.3 (0.1, 0.7)	0.5 (0.2, 1.0)	0.6 (0.2, 1.4)	0.5 (0.4, 0.7)
Serious hypersensitivity reactions ^e	0.1 (0.0, 0.4)	0.1 (0.0, 0.4)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.1 (0.0, 0.2)
Injection site reactions	3.3 (2.5, 4.2)	1.1 (0.6, 1.6)	1.2 (0.7, 1.9)	0.4 (0.1, 1.1)	1.7 (1.4, 2.0)

Data were pooled from the BE SURE, BE VIVID, and BE READY feeder trials, their OLE BE BRIGHT, BE RADIANT, and the BE RADIANT OLE. Data are presented for BKZ Total for the full pooled trial period, and separately for Years 1 (Weeks 0–52), 2 (Weeks 52–104), 3 (Weeks 104–156), and 4 (Weeks 156–208). Data were pooled for all patients who received ≥1 BKZ dose in each of the periods examined (BKZ Total). ^aContounding factors linked to the COVID-19 pandemic, including social isolation, mask-wearing, and lockdowns, may have impacted Year 3 and Year 4 data, particularly respiratory infection TEAEs such as nasopharyngitis; ^bThe EAIR for oral candidiasis over 4 years was numerically lower in patients receiving BKZ Q8W vs. Q4W (6.5/100 PY vs. 16.7/100 PY); ^cIncludes any TEAE adjudicated as definite or probable inflammatory bowel disease; ^dPatients with elevations >5x ULN were a subset of patients with elevations >3x ULN; ^eNo anaphylactic reactions associated with BKZ were reported.



To receive a copy of this poster, scan the QR code or visit: www.mdmh2025.com/PosterID:063516
Link expiration: February 7, 2025